Healthcare / Drug Manufacturers - Specialty & GenericBSE
$50.32
-1.06 (-2.07%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $4.0M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$722M
P/E
100.6x
↑EV/EBITDA
N/A
•ROE
6.3%
↑Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $15.6M · FCF $7.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $15.6M | $15.6M | $4.0M | $-590530.00 | $-1.0M |
| EBITDA | $-2.5M | $-2.5M | $-2.5M | $-563210.00 | $-977800.00 |
| EPS | — | — | 0.64 | -0.10 | -0.17 |
| Balance Sheet | |||||
| Debt/Equity | — | — | 0.01 | 0.08 | 0.02 |
| Cash Flow | |||||
| Free Cash Flow | $7.1M | $7.1M | $4.0M | $-29000.00 | $-1.5M |
| Returns | |||||
| ROE | 6.3% | 6.3% | 1.6% | -4.9% | -9.3% |
| Valuation | |||||
| P/E | 100.64 | 100.64 | 68.25 | — | — |
| P/B | 2.91 | 2.91 | 2.47 | — | — |
| Growth & Yield | |||||
| EPS Growth | — | — | 740.0% | 41.2% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.64 → n/d
Residual
+14.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.